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Introduction {#s1}
============

Breast cancer is the most common women\'s cancer and is a leading cause of cancer mortality [@pone.0109973-Jemal1]. Inherited genetic variation has been associated with the initiation, development and progression of breast cancer. Studies on twins have suggested that hereditary predisposing factors are involved in up to one third of all breast cancers [@pone.0109973-Lichtenstein1]. Many genetic loci have been associated with breast cancer risk and collectively explain approximately 35% of the familial risk [@pone.0109973-Ghoussaini1], [@pone.0109973-Michailidou1]. The largest genetic association study of breast cancer to date identified 41 novel low penetrance susceptibility loci [@pone.0109973-Michailidou1] by selecting nearly 30,000 SNPs from a meta-analysis of nine genome-wide association (GWA) studies and genotyping them using 41,785 cases and 41,880 controls of European ancestry from studies in the Breast Cancer Association Consortium (BCAC). These 41 susceptibility loci probably represent the tip of the ice berg, and additional SNPs from the combined GWAS might explain a similar fraction of familial risk to that attributed to the already identified loci [@pone.0109973-Michailidou1].

Mature miRNAs are 20--23 nucleotide, single-stranded RNA molecules that play a crucial role in gene expression regulation for many cellular processes including differentiation potential and development pattern. MiRNAs undergo a stepwise maturation process involving an array of miRNA machinery components. Drosha and DGCR8 mediate the cleavage of long primary miRNA transcripts (pri-miRNAs) into shorter pre-miRNAs in the nucleus [@pone.0109973-Denli1], [@pone.0109973-Lee1]. The pre-miRNAs are then transported to the cytoplasm where they are further cleaved by Dicer to produce mature miRNAs [@pone.0109973-Hutvagner1]. MiRNAs interact by pairing with the 3′ untranslated region (UTR), and also within the coding region and 5′ UTR of the corresponding mRNAs leading to mRNA destabilization, cleavage or translation repression. More effective mRNA destabilization is achieved when miRNA targets the 3\'UTR rather than other mRNA regions [@pone.0109973-Sosio1]--[@pone.0109973-Shukla1]. An individual miRNA may regulate approximately 100 distinct mRNAs, and together more than 1000 human miRNAs are believed to modulate more than half of the mRNA species encoded in the genome [@pone.0109973-Krol1], [@pone.0109973-Zhong1]. Additionally, most mRNAs possess binding sites for miRNAs [@pone.0109973-Friedman1]. MiRNAs are involved in tumorigenesis in that they can be either oncogenic when tumor suppressor genes are targeted, or genomic guardians (tumour suppressor miRNAs) when oncogenes are targeted [@pone.0109973-Farazi1]. Additionally it has been suggested that they may modulate both metastasis [@pone.0109973-Wang1] and chemotherapy resistance [@pone.0109973-Liang1]. MiRNAs have also been shown to have altered expression levels in tumours compared to normal tissue and between tumor subtypes in breast cancer among other carcinoma types [@pone.0109973-Volinia1]--[@pone.0109973-XX1]. SNPs may affect miRNA machinery genes or miRNAs activity; however SNPs can also create, abolish or modify miRNA binding sites in their binding regions. Polymorphisms in miRNA binding sites have been studied in regard to the risk of several cancers [@pone.0109973-Landi1], including breast cancer [@pone.0109973-Song1]--[@pone.0109973-Nicoloso1]. These studies have found evidence for association of miRNA related SNPs and cancer risk, but the study sample sizes have been relatively small.

In this study, we investigate associations between miRNA-related polymorphisms and breast cancer risk by using a meta-analysis of nine GWAS and subsequent genotyping of top hits using 41,785 cases and 41,880 controls of European ancestry from the BCAC. To our knowledge, this is thus far the largest investigation of associations between miRNA-related polymorphisms and breast cancer susceptibility.

Materials and Methods {#s2}
=====================

SNP selection and genotyping {#s2a}
----------------------------

SNPs in mature or pre-miRNAs, in genes of the miRNA machinery and in 3\'UTR regions of protein coding genes with a potential effect on miRNA binding were systematically searched from Ensembl (hg18/build36) and Patrocles databases [@pone.0109973-Hiard1]. Additionally, tagging SNPs for such with r^2^≥0.8 were also identified utilizing the public HapMap SNP database. By this *in silico* approach we identified altogether 147,801 candidate SNPs and 12,550 tagging SNPs. These SNPs were then overlayed with those from the combined GWAS from the BCAC [@pone.0109973-Michailidou1] and altogether 2196 SNPs were present (either genotyped or imputed) in the combined GWAS. These SNPs were genotyped with Illumina or Affymetrix arrays, as described previously [@pone.0109973-Dite1]--[@pone.0109973-Turnbull1]. The combined GWAS data were imputed for all scans using HapMap version 2 CEU as a reference in similar fashion to that presented by Michailidou and colleagues [@pone.0109973-Michailidou1] with the exception that the HapMap version 2 release 21 was used at the time the overlay was performed. Analysis using a 1-degree-of-freedom trend test of these 2196 SNPs in the combined GWAS indicated some evidence of association with breast cancer risk for 44 SNPs (p\<0.09). Notably, the combined GWAS included imputed data generated using HapMap version 2 release 21 (based on NCBI build 35 (dbSNP b125)), whereas the results presented here for the combined GWAS are based on imputation using HapMap version 2 release 22 (based on NCBI build 36 (dbSNP b126)). In the release 22, a number of SNPs were excluded due to mapping inconsistencies in build 35 relative to build 36. Hence, the estimates from the combined GWAS may slightly differ from the initial association analysis. The 44 SNPs (including 30 candidate and 14 tagging SNP) were genotyped on additional samples in the BCAC using the custom Illumina Infinium array (iCOGS) which included a total of 211,155 SNPs as described previously. The detailed description of quality control process for combined GWAS and iCOGS genotyping data was presented in [@pone.0109973-Michailidou1].

Of the 42 SNPs that passed quality control [@pone.0109973-Michailidou1], two were located in miRNA genes (one candidate SNP located in pre-miRNA hsa-miR-2110 and one tag SNP tagging a mature hsa-mir-548l variant), and four SNPs were located in miRNA machinery genes (*SMAD5*, *SND1*, *CNOT4* and *DROSHA*). The genotyped *DROSHA* SNP tags the 3′ UTR miRNA binding site variant in the DROSHA gene. The remaining 38 candidate or tag SNPs were located in, or tagged to a predicted miRNA binding site in the 3′ UTR of protein coding genes. All 42 SNPs are described in [Table 1](#pone-0109973-t001){ref-type="table"}. The workflow of the SNP selection in different stages is illustrated in [Figure 1](#pone-0109973-g001){ref-type="fig"}.

![Workflow of miRNA SNP selection.](pone.0109973.g001){#pone-0109973-g001}
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###### The 42 studied SNPs in miRNAs, miRNA machinery genes and miRNA target genes.

![](pone.0109973.t001){#pone-0109973-t001-1}

  Functional SNP (Tag SNP, R-squared)            Chr   Position    Coding       Gene                                                   miRNA                                                SNP effect[a](#nt102){ref-type="table-fn"}
  --------------------------------------------- ----- ----------- -------- -------------- ------------------------------------------------------------------------------------------------ --------------------------------------------
  Located within miRNA                                                                                                                                                                     
  rs17091403                                     10    115923895     GA     hsa-miR-2110                                                                                                   
  rs13447640 (rs1805360, r^2^ = 1)               11    93866677      GA     hsa-mir-548l                                                                                                   
  Located in miRNA biogenesis machinery genes                                                                                                                                              
  rs3764941                                       5    135497426     AC        SMAD5                                                                                                       
  rs17151639                                      7    127425052     AG         SND1                                                                                                       
  rs17480616                                      7    134773600     CG        CNOT4                                                                                                       
  rs10719                                         5    31437204      GA        DROSHA                                               hsa-miR-1298                                                                AC
  Located in miRNA target genes                                                                                                                                                            
  rs2550303                                      16    54953111      AG         AMFR                                                hsa-miR-577                                                                 AC
  rs7513934                                       1    52590776      GA        CC2D1B                                         hsa-miR-384/hsa-miR-577                                                          CNC
  rs1128226                                       7    21908194      AC        CDCA7L                                               hsa-miR-548g                                                                AC
  rs3796133                                       3    100000533     GA        DCBLD2                                              hsa-miR-624\*                                                                AC
  rs7441                                         12    90063806      GA         DCN                                                hsa-miR-135b\*                                                               AC
  rs1803439                                      21    37807312      AG        DYRK1A                                               hsa-miR-550                                                                 AC
  rs3797                                         15    27199858      AG       FAM189A1                                              hsa-miR-570                                                                 AC
  rs7130622                                      11    128186721     AC         FLI1                                              hsa-miR-138-2\*                                                               AC
  rs1052532                                      15    89275240      AG        HDDC3                                 hsa-miR-1224-3p/hsa-miR-1260/hsa-miR-1280                                                  AC
  rs7040123                                       9     7160742      AG        KDM4C                                         hsa-miR-154\*/hsa-miR-487a                                                         AC
  rs1062225                                      10    49313232      AG        MAPK8                                                hsa-miR-203                                                                 AC
  rs41739                                         7    116224740     AG         MET                                                hsa-miR-576-5p                                                               AC
  rs702681                                        5    56253786      AG        MIER3                                               hsa-miR-196a\*                                                               AC
  rs3134615                                       1    40134653      CA        MYCL1                                                hsa-miR-1827                                                               ANC
  rs2304669                                       2    238830402     AG         PER2                                               hsa-miR-885-3p                                                               AC
  rs13422                                        17    15074900      AC        PMP22                                              hsa-miR-29b-1\*                                                               AC
  rs7562391                                       2    201444411     AC        PPIL3                                        hsa-miR-493\*/hsa-miR-499-3p                                                        AC
  rs7520333                                       1    40862837      AG        RIMS3                                           hsa-let-7d/hsa-let-7e                                                           CNC
  rs739692                                       18    53178524      GA       ST8SIA3                                   hsa-miR-96/hsa-miR-1271/hsa-miR-182                                                     AC
  rs1058450                                       4    120200088     GA        SYNPO2                                               hsa-miR-183                                                                 AC
  rs4351800                                      11     7446395      CA         SYT9                                                hsa-miR-544                                                                 AC
  rs12438324                                     15    55366808      AG        TCF12                                                hsa-miR-591                                                                 AC
  rs12869870                                     13    99415306      GA         ZIC5                            hsa-miR-34a/hsa-miR-34c-5p/hsa-miR-449a/hsa-miR-449b                                            AC
  rs9990 (rs1444418, r^2^ = 1)                   10    64230476      AG         ADO                                          hsa-miR-512-5p/hsa-miR-510                                                         AC
  rs757537 (rs4705870, r^2^ = 1)                  5    132187033     GA       ANKRD43                           hsa-miR-320a/hsa-miR-320b/hsa-miR-320c/hsa-miR-320d                                             AC
  rs3774729 (rs2037119, r^2^ = 0.943)             3    63969919      GA        ATXN7                                                hsa-miR-1206                                                                AC
  rs1045487 (rs1045494, r^2^ = 1)                 2    201860026     AG        CASP8                                                hsa-miR-938                                                                 AC
  rs7288826 (rs8140217, r^2^ 1)                  22    37547947      GA         CBX6                                              hsa-miR-1207-5p                                                               AC
  rs17569034 (rs17512204, r^2^ = 0.835)           2    118449301     GA        CCDC93                                               hsa-miR-1178                                                                AC
  rs3205281 (rs7674744, r^2^ = 1)                 4    78874296      GA        CNOT6L                                         hsa-miR-643/hsa-miR-297                                                           AC
  rs13005 (rs9473, r^2^ = 0.964)                 10    13727177      GA        FRMD4A                                               hsa-miR-548m                                                                AC
  rs3809831 (rs3809828, r^2^ = 1)                17     7187575      GA        KCTD11                                               hsa-miR-892b                                                                AC
  rs6445538 (rs4687554, r^2^ = 1)                 3    52839175      AG        MUSTN1                                               hsa-miR-891b                                                                AC
  rs7818 (rs9371201, r^2^ = 0.875)                6    150186694     GA        PCMT1                                                hsa-miR-595                                                                 AC
  rs9844202 (rs7635553, r^2^ = 1)                 3    168646064     GA       SERPINI2                                              hsa-miR-1272                                                                AC
  rs2271565 (rs7086917, r^2^ = 1)                10    49867441      AC        WDFY4       hsa-miR-657/hsa-miR-214/hsa-miR-15a/hsa-miR-16/hsa-miR-15b/hsa-miR-195/hsa-miR-424/hsa-miR-497                       AC

Tag SNPs used in the analysis are presented in the parenthesis along with the R squred value relative to the functional SNP.

According to Patrocles prediction; AC  =  abolishes conserved binding site, ANC  =  abolishes non-conserved binding site, CNC  =  creates non-conserved binding site (Target sites are considered conserved if they are shared by at least one primate, one rodent and one nonprimate/nonrodent mammal [@pone.0109973-Hiard1]).

Study sample {#s2b}
------------

The combined GWAS included nine breast cancer studies totalling 10,052 cases and 12,575 controls of European ethnic background. Details and study-specific subject numbers are presented in [Table S1](#pone.0109973.s003){ref-type="supplementary-material"}. Since the GWAS were limited to patients of European ethnic background we further utilized 41,785 cases ascertained for their first primary, invasive breast cancer and 41,880 controls of European ancestry from 41 BCAC studies genotyped using the iCOGS array ([Table S2](#pone.0109973.s004){ref-type="supplementary-material"}). For a subgroup analysis of ER negative and ER positive cases, as well as cases aged less than 50 years at diagnosis, we included all the cases for which the respective data were available. The ER subgroup analysis was based on 702 ER negative cases and 2,019 ER positive cases from five GWAS studies and 7,200 ER negative cases from 40 BCAC studies and 26,302 ER positive cases from 34 BCAC studies. The analysis of cases aged less than 50 years at diagnosis was based on 3,470 cases from three GWAS studies and 9,483 cases from 35 BCAC studies. All participating studies conform to the Declaration of Helsinki and were approved by the respective ethical review boards and ethics committees ([Tables S1](#pone.0109973.s003){ref-type="supplementary-material"} and [S2](#pone.0109973.s004){ref-type="supplementary-material"}), and all participants in these studies had provided written consent for the research.

Statistical methods {#s2c}
-------------------

We used logistic regression to estimate per-allele log-odds ratios and standard errors including the study as a covariate. We also included principal components as covariates in order to correct for potential hidden population structure. In the GWAS, for two studies (UK2 and HEBCS) the estimates were adjusted for the first three principal components and in the iCOGS analysis we used the first six principal components and an additional component to reduce inflation for the LMBC study, as described previously [@pone.0109973-Michailidou1]. Subgroup analyses were carried out for ER negative and positive subgroups and for the group aged less than 50 years at diagnosis. For meta-analysis, we combined the estimates from the combined GWAS and iCOGS with a fixed effects model using the inverse variance weighted method. In the meta-analysis, the subjects involved in both combined GWAS and iCOGS (1880) were only taken into account once. In order to adust for *P*-values against multiple testing, we used Benjamini Hochberg correction. The adjusted *P*-values are shown in [Table 2](#pone-0109973-t002){ref-type="table"} along with the nominal *P*-values. In the text we report the nominal *P*-values. The statistical analyses were conducted using the R 2.14.0 statistical computing environment (<http://www.r-project.org/>).

10.1371/journal.pone.0109973.t002

###### Associations of SNPs in the GWAS and iCOGS separately and combined GWAS + iCOGS and breast cancer risk.

![](pone.0109973.t002){#pone-0109973-t002-2}

  SNP           Chr   Position    coding[1](#nt104){ref-type="table-fn"}   GWAS OR (95%CI)[2](#nt105){ref-type="table-fn"}   GWAS *P* [3](#nt106){ref-type="table-fn"}   iCOGS OR (95% CI)[2](#nt105){ref-type="table-fn"}   iCOGS *P* [3](#nt106){ref-type="table-fn"}   Combined GWAS + iCOGS OR (95% CI)[2](#nt105){ref-type="table-fn"}   Combined GWAS + iCOGS *P* [3](#nt106){ref-type="table-fn"}(BH corrected *P*)[4](#nt107){ref-type="table-fn"}     Gene
  ------------ ----- ----------- ---------------------------------------- ------------------------------------------------- ------------------------------------------- --------------------------------------------------- -------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ----------
  rs702681       5    56253786                      AG                                    1.07 (1.02--1.11)                                 3.92×10^−3^                                  1.06 (1.04--1.09)                                  2.76×10^−8^                                           1.06 (1.04--1.08)                                                                    3.88×10^−10^ (1.63×10^−8^)                                             MIER3
  rs1045494      2    201860026                     AG                                    0.90 (0.81--1.00)                                 4.74×10^−2^                                  0.92 (0.88--0.96)                                  4.47×10^−4^                                           0.92 (0.88--0.96)                                                                    5.94×10^−5^ (1.25×10^−3^)                                              CASP8
  rs1052532     15    89275240                      AG                                    0.94 (0.90--0.98)                                 7.94×10^−3^                                  0.97 (0.95--0.99)                                  1.47×10^−2^                                           0.97 (0.95--0.99)                                                                    7.78×10^−4^ (1.09×10^−2^)                                              HDDC3
  rs10719        5    31437204                      GA                                    0.92 (0.88--0.97)                                 8.79×10^−4^                                  0.98 (0.95--1.00)                                  5.32×10^−2^                                           0.97 (0.94--0.99)                                                                    1.35×10^−3^ (1.42×10^−2^)                                              DROSHA
  rs4687554      3    52839175                      AG                                    0.94 (0.90--0.99)                                 1.23×10^−2^                                  0.97 (0.95--1.00)                                  2.39×10^−2^                                           0.97 (0.95--0.99)                                                                    1.71×10^−3^ (1.44×10^−2^)                                              MUSTN1
  rs3134615      1    40134653                      CA                                    1.04 (0.99--1.09)                                 9.97×10^−2^                                  1.03 (1.00--1.05)                                  2.09×10^−2^                                           1.03 (1.01--1.05)                                                                    5.07×10^−3^ (3.55×10^−2^)                                              MYCL1
  rs7635553      3    168646064                     GA                                    0.89 (0.83--0.95)                                 9.73×10^−4^                                  0.98 (0.95--1.01)                                  1.98×10^−1^                                           1.00 (0.97--1.04)                                                                    9.24×10^−3^ (5.54×10^−2^)                                             SERPINI2
  rs3796133      3    100000533                     GA                                    1.18 (1.08--1.29)                                 4.18×10^−4^                                  1.01 (0.97--1.06)                                  5.74×10^−1^                                           1.04 (1.00--1.09)                                                                    3.93×10^−2^ (1.45×10^−1^)                                              DCBLD2
  rs4351800     11     7446395                      CA                                    1.04 (1.00--1.08)                                 4.48×10^−2^                                  1.01 (0.99--1.03)                                  1.98×10^−1^                                           1.02 (1.00--1.04)                                                                    4.15×10^−2^ (1.45×10^−1^)                                               SYT9
  rs17512204     2    118449301                     GA                                    1.06 (0.98--1.14)                                 1.20×10^−1^                                  1.03 (0.99--1.06)                                  1.63×10^−1^                                           1.03 (1.00--1.07)                                                                    5.22×10^−2^ (1.57×10^−1^)                                              CCDC93
  rs3809828     17     7187575                      GA                                    1.17 (1.06--1.28)                                 1.97×10^−3^                                  1.01 (0.97--1.05)                                  5.22×10^−1^                                           0.99 (0.95--1.03)                                                                    7.93×10^−2^ (2.22×10^−1^)                                              KCTD11
  rs7441        12    90063806                      GA                                    1.11 (1.03--1.20)                                 8.70×10^−3^                                  1.01 (0.97--1.05)                                  5.98×10^−1^                                           1.03 (0.99--1.06)                                                                    1.04×10^−1^ (2.57×10^−1^)                                               DCN
  rs7086917     10    49867441                      AC                                    0.96 (0.93--1.00)                                 6.35×10^−2^                                  0.99 (0.97--1.01)                                  4.38×10^−1^                                           0.99 (0.97--1.00)                                                                    1.29×10^−1^ (3.01×10^−1^)                                              WDFY4
  rs7040123      9     7160742                      AG                                    1.11 (0.99--1.23)                                 7.59×10^−2^                                  1.02 (0.97--1.07)                                  5.14×10^−1^                                           1.00 (0.95--1.04)                                                                    1.79×10^−1^ (3.74×10^−1^)                                              KDM4C
  rs7674744      4    78874296                      GA                                    0.94 (0.89--0.99)                                 2.83×10^−2^                                  0.99 (0.97--1.02)                                  6.91×10^−1^                                           1.01 (0.98--1.03)                                                                    1.81×10^−1^ (3.74×10^−1^)                                              CNOT6L
  rs12438324    15    55366808                      AG                                    0.87 (0.79--0.97)                                 1.01×10^−2^                                  1.00 (0.94--1.05)                                  8.69×10^−1^                                           1.02 (0.98--1.07)                                                                    1.87×10^−1^ (3.74×10^−1^)                                              TCF12
  rs17151639     7    127425052                     AG                                    0.96 (0.92--1.01)                                 1.09×10^−1^                                  0.99 (0.97--1.02)                                  5.66×10^−1^                                           1.00 (0.98--1.02)                                                                    2.19×10^−1^ (4.18×10^−1^)                                               SND1
  rs17480616     7    134773600                     CG                                    0.87 (0.72--1.04)                                 1.27×10^−1^                                  0.99 (0.93--1.04)                                  6.39×10^−1^                                           0.98 (0.92--1.03)                                                                    3.70×10^−1^ (5.98×10^−1^)                                              CNOT4
  rs7513934      1    52590776                      GA                                    1.04 (1.00--1.08)                                 7.98×10^−2^                                  1.00 (0.98--1.02)                                  9.99×10^−1^                                           1.01 (0.99--1.02)                                                                    4.37×10^−1^ (6.34×10^−1^)                                              CC2D1B
  rs2304669      2    238830402                     AG                                    0.96 (0.91--1.02)                                 1.86×10^−1^                                  1.00 (0.97--1.02)                                  8.17×10^−1^                                           0.99 (0.97--1.02)                                                                    4.38×10^−1^ (6.34×10^−1^)                                               PER2
  rs1058450      4    120200088                     GA                                    0.96 (0.91--1.01)                                 1.33×10^−1^                                  1.00 (0.97--1.02)                                  9.28×10^−1^                                           1.01 (0.98--1.03)                                                                    4.59×10^−1^ (6.43×10^−1^)                                              SYNPO2

The SNPs with consistent odds ratios in combined GWAS and iCOGS analysis are shown. (Results for all 42 SNPs are presented in [Table S3](#pone.0109973.s005){ref-type="supplementary-material"}.)

Build 36 position.

Per allele odds ratio for the minor allele relative to the major allele.

1df p-trend.

1df p-trend adjusted against multiple testing by Benjamini--Hochberg correction method.

Results {#s3}
=======

For the 42 SNPs we successfully genotyped, estimates of association from the combined GWAS and from iCOGS analysis are shown in [Table S3](#pone.0109973.s005){ref-type="supplementary-material"}. Twenty-one SNPs showed consistent associations with breast cancer risk in the combined GWAS and in iCOGS analysis; results from the meta-analysis are shown in [Table 2](#pone-0109973-t002){ref-type="table"}. The most significantly associated SNP, rs702681 (OR 1.06 \[95%CI 1.04--1.08\]; *P* 3.9×10^−10^), is located in the 3\'UTR of MIER3, close to the known breast cancer susceptibility gene MAP3K1. The SNP rs702681 is located at the same 5q11.2 locus as the previously published risk SNP rs889312 [@pone.0109973-Easton1] (correlation r^2^ = 0.3). When the two SNPs were analysed in the same logistic regression model, the association with rs889312, but not that with rs702681 remained nominally statistically significant, suggesting that rs702681 is unlikely to be the causal SNP at this locus. The five SNPs with the significant novel associations from the meta-analysis (*P*≤5.07×10^−3^and adjusted *P*≤3.55×10^−2^ after correction for multiple testing) were rs1045494, (OR 0.92 \[95%CI 0.88--0.96\]; *P* =  5.90×10^−5^), rs1052532, (OR 0.97 \[95%CI 0.95--0.99\]; *P* = 7.78×10^−4^), rs10719, (OR 0.97 \[95%CI 0.94--0.99\]; *P* = 1.35×10^−3^) rs4687554 (OR 0.97 \[95%CI 0.95--0.99\]; *P* = 1.71×10^−3^) and rs3134615 (OR 1.03 \[95%CI 1.01--1.05\]; *P* = 5.07×10^−3^) located in 3′ UTR of Caspase-8 (*CASP8*), HD Domain Containing 3 (*HDDC3*), *DROSHA*, Musculoskeletal, Embryonic Nuclear Protein 1 (*MUSTN1*) and V-Myc Myelocytomatosis Viral Oncogene Homolog 1 (*MYCL1*), respectively ([Table 2](#pone-0109973-t002){ref-type="table"}). SNP rs1045494 is tagging the hsa-miR-938 binding site SNP rs1045487 (r^2^ = 1.0) of CASP8 and the SNP rs1052532 in *HDDC3* is predicted to abolish the binding site for hsa-miR-1224-3p. The SNP rs10719 is predicted to abolish the hsa-miR-1298 binding site in the 3′ UTR of *DROSHA*. SNP rs4687554 tags the hsa-miR-891b binding site SNP rs6445538 (r^2^ = 1.0) of *MUSTN1* and rs3134615 is located at the binding site of hsa-miR-1827 of *MYCL1*. There was no evidence for heterogeneity in the per-allele OR for any SNP. The per study per allele ORs for these five miRNA binding site SNPs from the combined GWAS along with per-SNP heterogeneity variance *P*-values are shown in [Figure S1](#pone.0109973.s001){ref-type="supplementary-material"} and from the iCOGS in [Figure S2](#pone.0109973.s002){ref-type="supplementary-material"}. Next we analysed the SNPs by ER status-defined subtype, and for cases aged less than 50 years at diagnosis, for risk associations in the meta-analysis of combined GWAS and iCOGS ([Tables S4](#pone.0109973.s006){ref-type="supplementary-material"}, [S5](#pone.0109973.s007){ref-type="supplementary-material"} and [S6](#pone.0109973.s008){ref-type="supplementary-material"}). These analyses did not reveal any additional significant results. For rs1045494 in *CASP8*, rs4687554 in *MUSTN1* and rs3134615 in *MYCL1* (OR 1.03 \[95%CI 1.01--1.05\]; *P* = 7.75×10^−4^) a more significant association with breast cancer risk was found for the ER positive subgroup than in the main analysis, but the result from the test for heterogeneity by ER status was not significant (data not shown). All associations were estimated using an additive inheritance model. Dominant and recessive models did not improve the estimates (data not shown).

Discussion {#s4}
==========

We investigated associations between genetic variation in miRNAs, in the genes of the miRNA machinery and in the miRNA binding sites and the risk of breast cancer. We identified several SNPs that are predicted to abolish an miRNA binding site and that are significantly associated with breast cancer risk. Previous studies investigating miRNA related SNPs, especially in miRNA binding sites have included predefined sets of genes. Nicoloso and colleagues investigated 38 previously identified breast cancer risk SNPs and found two to modify miRNA binding sites in TGFB1 and XRCC1 in vitro [@pone.0109973-Nicoloso1]. Neither of these were included in our data set. Liang and colleagues investigated 134 potential miRNA binding sites in cancer-related genes and found six miRNA binding site SNPs that were associated with ovarian cancer risk [@pone.0109973-Liang2].

In the meta-analysis of combined GWAS and iCOGS for main effects, for four of the five most significant miRNA binding site SNPs, the minor allele was associated with a decreased breast cancer risk. The minor allele of SNP rs3134615 in 3′ UTR of *MYCL1* was associated with an increased breast cancer risk. All the five most significant miRNA binding site SNPs locate in 3′ UTR and have been predicted to abolish the miRNA binding site. The defect in miRNA-mediated regulation would be expected to lead to an increase in the translation of the corresponding encoded protein. The five genes, whose regulation may be affected by the miRNA-associated SNPs, include the pre-apoptotic gene *CASP8*, *HDDC3*, miRNA biogenesis master regulator *DROSHA*, MYC-family member *MYCL1* and *MUSTN1*. *CASP8* is involved in apoptosis in breast cancer cells [@pone.0109973-RuizRuiz1], and many studies have reported polymorphisms in this gene to be associated with risks for several cancers [@pone.0109973-Barrett1], [@pone.0109973-deMartino1] including breast cancer [@pone.0109973-Cox1], [@pone.0109973-Peng1], indicating the importance of *CASP8* in tumor development. SNP rs1045494 studied here is located close to the coding region SNP rs1045485 that has been previously shown to have a stronger protective effect [@pone.0109973-Cox1], [@pone.0109973-MacPherson1], [@pone.0109973-Frank2]. Interestingly, Michalidou and colleagues reported this SNP as having only weak evidence for an association (*P* 0.0013 in combined GWAS and iCOGS) [@pone.0109973-Michailidou1], but these two SNPs (rs1045485 and rs1045494) are not correlated (r^2^ = 0.001 in Caucasian population). Neither is rs1045494 correlated with the more strongly associated rs1830298 SNP, identified through fine-mapping of the region (r^2^ = 0.02) [@pone.0109973-Lin1]. Rs1045494 tags SNP rs1045487 (r^2^ = 1.0) which is predicted to abolish the hsa-miR-938 binding site and thus may affect *CASP8* expression. There is very little reported evidence on the involvement of *HDDC3* or the hsa-miR-1224-3p in cancer, indicating a novel association with risk. *HDDC3* has been suggested to be involved in the starvation response [@pone.0109973-Sun1]. The *HDDC3* gene is expressed at higher levels by several different tumor types, including breast tumors, than by normal tissue [@pone.0109973-Kilpinen1]. *DROSHA* is a miRNA master regulator. It is a member of the RNase III enzyme family, belongs to the miRNA biogenesis pathway and is the core nuclease that processes pri-miRNAs into pre-miRNAs in the nucleus [@pone.0109973-Denli1], [@pone.0109973-Lee1]. The SNP rs10719 in the 3′ UTR of *DROSHA* is predicted to abolish the hsa-miR-1298 binding site. Hsa-miR-1298 is predicted to target *DROSHA* by the Patrocles prediction as well as by TargetScan [@pone.0109973-Lewis1] and PITA [@pone.0109973-Kertesz1] prediction algorithms. Recently a small Korean study reported another SNP rs644236, tagging the SNP rs10719 (r^2^ = 0.955 in CEU population and r^2^ = 0.876 in Asian population (combined CHB and JPT)) to be associated with elevated breast cancer risk [@pone.0109973-Sung1]. When taking into account the opposite major and minors alleles in the Asian and European populations for SNPs rs644236 and rs10719, this result is in concordance with our results where both the combined GWAS as well as the iCOGS analysis consistently indicated an association of the minor allele of SNP rs10719 with reduced breast cancer risk. We also found the minor allele of SNP rs3134615 in the 3′ UTR of *MYCL1* to be associated with an increased risk. *MYCL1* (L-MYC) belongs to the same family of transcription factors as the known proto-oncogene MYC (*C-MYC*) and they share a high degree of structural similarity [@pone.0109973-Birrer1]. The *MYCL1* gene has previously been reported to be amplified and overexpressed in ovarian cancer [@pone.0109973-Wu1]. A case-control study by Xiong and colleagues reported SNP rs3134615 to be significantly associated with increased risk of small cell lung cancer [@pone.0109973-Xiong1]. SNP rs3134615 was predicted by Patrocles to abolish the hsa-miR-1827 binding site. This has also been suggested by functional studies where *MYCL1* was found as the target of hsa-miR-1827 and the SNP rs3134615 was also found to increase *MYCL1* expression [@pone.0109973-Xiong1]. The evidence from functional studies is consistent with our finding that SNP rs3134615 might increase breast cancer risk. *MUSTN1* has been shown to be involved in the development and regeneration of the musculoskeletal system [@pone.0109973-Lombardo1]. Thus far no evidence of association between *MUSTN1* and breast cancer has been reported, but the *MUSTN1* gene is expressed in the mammary glands [@pone.0109973-Kapushesky1].

Since only a small fraction of miRNA binding sites has been experimentally validated, we selected SNPs that had been computationally predicted to affect miRNA binding sites. For our original SNP selection we used the Patrocles database that contains predicted miRNA binding sites and also compiles perturbation prediction of SNP effects. There are a multitude of prediction programs and their performance has been evaluated [@pone.0109973-Witkos1]. Witkos and colleagues find target prediction algorithms that utilize orthologous sequence alignment, like Patrocles, to be the most reliable.

The followup of the 42 miRNA related SNPs identified five significant associations with breast cancer risk. Although the individual risk effects were subtle, considering that we could only investigate a small proportion of our initial *in silico* data set of miRNA related SNPs (over 140,000 SNPs) this may suggest that genetic polymorphisms affecting the miRNA regulation could have a considerable combined effect on breast cancer risk.

It should be noted that, until fine mapping studies are carried out for these loci, it is not clear whether these miRNA-related SNPs are the variants responsible for the observed associations.

This comprehensive analysis of miRNA related polymorphisms using a large two stage study of women with European ancestry provides evidence for miRNA related SNPs being potential modulators of breast cancer risk.
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